Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02290327




Registration number
NCT02290327
Ethics application status
Date submitted
31/10/2014
Date registered
14/11/2014
Date last updated
8/02/2016

Titles & IDs
Public title
Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU
Scientific title
Secondary ID [1] 0 0
REV-06MAR14
Universal Trial Number (UTN)
Trial acronym
REVISE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Stress Ulcer Prophylaxis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pantoprazole
Treatment: Drugs - Placebo

Placebo comparator: Placebo - 50 ml of 0.9% Normal Saline Intravenously once daily

Active comparator: Pantoprazole - Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily


Treatment: Drugs: Pantoprazole
Proton pump inhibitor

Treatment: Drugs: Placebo
50 ml of 0.9% normal saline
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Consent Rate
Timepoint [1] 0 0
12 months
Primary outcome [2] 0 0
Recruitment Rate
Timepoint [2] 0 0
12 months
Primary outcome [3] 0 0
Protocol Adherence
Timepoint [3] 0 0
12 months
Secondary outcome [1] 0 0
Clinically important upper gastrointestinal bleeding
Timepoint [1] 0 0
During ICU stay (expected average is 10 days)
Secondary outcome [2] 0 0
Ventilator associated pneumonia
Timepoint [2] 0 0
During ICU stay (expected average is 10 days)
Secondary outcome [3] 0 0
Mortality
Timepoint [3] 0 0
During ICU and hospital stay (expected average ICU stay is 10 days, expected average hospital stay is 30 days)
Secondary outcome [4] 0 0
Clostridium Difficile infection
Timepoint [4] 0 0
During ICU stay (expected average ICU stay is 10 days)

Eligibility
Key inclusion criteria
1. Adults = 18 years
2. Anticipated invasive mechanical ventilation of =48 hours, determined by the intensivist
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Invasive mechanical ventilation >72 hours before randomization.
2. Patients who must receive PPI due to active bleeding or increased bleeding risk (e.g., patients with acute GI bleeding, recent severe esophagitis, Zollinger Ellison syndrome, Barrett's esophagus, peptic ulcer bleeding within 8 weeks [mild dyspepsia or mild gastroesophageal reflex disease will not be excluded])
3. Receiving dual antiplatelet therapy aspirin and clopidogrel prior to randomization
4. Palliative care or decision to withdraw advanced life support (patients with a decision to forgo cardiopulmonary resuscitation will not be excluded)
5. Previous enrolment in this or a related trial
6. Pregnancy
7. Physician, patient, or substitute decision maker (SDM) declines
8. Two or more 'daily doses' of prophylaxis with H2RA or PPI (one day of a single PPI dose is not an exclusion criterion if once daily dosing of PPI prophylaxis was administered; one day of bid [twice daily] dosing of an H2RA is not an exclusion criterion if twice daily H2RA prophylaxis was administered; one day of tid [thrice daily] dosing of an H2RA is not an exclusion criterion if thrice daily H2RA prophylaxis was administered).

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
91
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide - Adelaide
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Nova Scotia
Country [2] 0 0
Canada
State/province [2] 0 0
Ontario
Country [3] 0 0
Saudi Arabia
State/province [3] 0 0
Eastern Province

Funding & Sponsors
Primary sponsor type
Other
Name
McMaster University
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
The Physicians' Services Incorporated Foundation
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Waleed Alhazzani, MD,FRCPC,MSc
Address 0 0
McMaster University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02290327